 |
|
  |
|
         
|
<< wοΦίι @Nearly every clinical analysis of cytoreductive surgery (CRS) for advanced ovarian carcinoma has documented its therapeutic efficacy and that the efficacy is directly correlated with the completeness of the resection. Nevertheless, there continues to be controversy about its place in management of this serious disease with respect to the specific indications, the radicalness and the risk of serious complications. In this presentation, the author will review the relevant literature, correlate the findings with clinical practice and provide his assessment of these findings in the context of his personal experience. The authorfs approach to CRS depends upon separating the tumor sites intogzoneshwhich include the pelvis, the right upper quadrant, the left upper quadrant, the omentum & transverse colon, and the retroperitoneum. The surgeon assesses these zones for resectablity and then proceeds from zone to zone with the goal of completely remove all macroscopic cancer. If the extent of cancer is such that the zones are confluent, in all probability the cancer is unresectable. The literature on CRS will be analyzed and presented for each of these areas:the radical oophorectomy, diaphragm stripping and resection, splenectomy, bowel resection and lymphadenectomy. Data on primary and secondary cytoreductive surgery will be addressed including the the role of neoadjuvant chemotherapy and the selection of patients for radical CRS. ϊ{YΘwlΘwοΦAnϋοορ, 42(3) 286-286, 2005 |
||
|
κΚΠc@lΦAYΘwlΘwο±Η@§102-0083 sηγcζ¬4-7 ¬p[NTChr402 )MARxVRTeBOΰ TELF03-3288-0993@FAXF03-5275-1192@E-mailFkantorengo@jsog-k.jp Copyright (C) κΚΠc@lΦAYΘwlΘwο |